PL376823A1 - Środki przeciwzakaźne - Google Patents

Środki przeciwzakaźne

Info

Publication number
PL376823A1
PL376823A1 PL376823A PL37682303A PL376823A1 PL 376823 A1 PL376823 A1 PL 376823A1 PL 376823 A PL376823 A PL 376823A PL 37682303 A PL37682303 A PL 37682303A PL 376823 A1 PL376823 A1 PL 376823A1
Authority
PL
Poland
Prior art keywords
infective agents
infective
agents
Prior art date
Application number
PL376823A
Other languages
English (en)
Inventor
John K. Pratt
David A. Betebenner
Pamela L. Donner
Brian E. Green
Dale J. Kempf
Keith F. Mcdaniel
Clarence J. Maring
Vincent S. Stoll
Rong Zhang
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/285,714 external-priority patent/US20040097492A1/en
Priority claimed from US10/625,121 external-priority patent/US20040162285A1/en
Priority claimed from US10/679,881 external-priority patent/US20050075331A1/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of PL376823A1 publication Critical patent/PL376823A1/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/69Two or more oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL376823A 2002-11-01 2003-10-31 Środki przeciwzakaźne PL376823A1 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/285,714 US20040097492A1 (en) 2002-11-01 2002-11-01 Anti-infective agents
US10/410,853 US20040087577A1 (en) 2002-11-01 2003-04-10 Anti-infective agents
US10/625,121 US20040162285A1 (en) 2002-11-01 2003-07-23 Anti-infective agents
US10/679,881 US20050075331A1 (en) 2003-10-06 2003-10-06 Anti-infective agents

Publications (1)

Publication Number Publication Date
PL376823A1 true PL376823A1 (pl) 2006-01-09

Family

ID=32314949

Family Applications (1)

Application Number Title Priority Date Filing Date
PL376823A PL376823A1 (pl) 2002-11-01 2003-10-31 Środki przeciwzakaźne

Country Status (8)

Country Link
EP (2) EP1560827B1 (pl)
KR (1) KR20050065670A (pl)
AU (1) AU2003291670A1 (pl)
BR (1) BR0315897A (pl)
CA (1) CA2504385C (pl)
MX (1) MXPA05004670A (pl)
PL (1) PL376823A1 (pl)
WO (1) WO2004041818A1 (pl)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101624391A (zh) 2001-06-11 2010-01-13 病毒化学医药公司 用作黄病毒感染抗病毒剂的噻吩衍生物
US7902203B2 (en) 2002-11-01 2011-03-08 Abbott Laboratories, Inc. Anti-infective agents
CN100413861C (zh) 2002-12-10 2008-08-27 维勒凯姆制药股份有限公司 用于治疗或预防黄病毒感染的化合物
ATE437875T1 (de) 2004-08-23 2009-08-15 Hoffmann La Roche Heterozyklische antivirale verbindungen
US7776847B2 (en) 2005-02-25 2010-08-17 Rigel Pharmaceuticals, Inc. Benzisothiazoles useful for treating or preventing HCV infection
CN101189230A (zh) * 2005-05-04 2008-05-28 弗·哈夫曼-拉罗切有限公司 抗病毒的杂环化合物
KR20080094834A (ko) 2006-02-17 2008-10-24 에프. 호프만-라 로슈 아게 헤테로사이클릭 항바이러스 화합물
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
WO2008011337A1 (en) * 2006-07-19 2008-01-24 Abbott Laboratories Hcv inhibitors
HRP20110193T1 (hr) 2006-10-10 2011-05-31 Medivir Ab Inhibitor hcv nukleozida
CN102675279A (zh) 2006-11-15 2012-09-19 Viro化学制药公司 用于治疗或预防黄病毒属感染的噻吩类似物
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
UA100120C2 (en) 2007-04-03 2012-11-26 Анадис Фармасьютикалз, Инк. 5,6-dihydro-1h-pyridin-2-one compounds
EP2494991A1 (en) 2007-05-04 2012-09-05 Vertex Pharmaceuticals Incorporated Combination therapy for the treatment of HCV infection
BRPI0817101A2 (pt) 2007-09-14 2017-05-09 Addex Pharmaceuticals Sa 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-dissubstituídas
SI2203439T1 (sl) 2007-09-14 2011-05-31 Ortho Mcneil Janssen Pharm 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni
ES2409215T3 (es) 2007-09-14 2013-06-25 Janssen Pharmaceuticals, Inc. 4-fenil-1H-piridin-2-onas 1-3-disustituidas
ES2637794T3 (es) 2007-11-14 2017-10-17 Janssen Pharmaceuticals, Inc. Derivados de imidazo[1,2-A]piridina y su uso como moduladores alostéricos positivos de receptores MGLUR2
CN103483251A (zh) 2007-12-19 2014-01-01 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
GB0800855D0 (en) * 2008-01-17 2008-02-27 Syngenta Ltd Herbicidal compounds
WO2010010017A1 (en) * 2008-07-23 2010-01-28 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
ES2439291T3 (es) 2008-09-02 2014-01-22 Janssen Pharmaceuticals, Inc. Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
CA2738849C (en) 2008-10-16 2016-06-28 Addex Pharma S.A. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
ES2401691T3 (es) 2008-11-28 2013-04-23 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Derivados de indol y de benzoxacina como moduladores de los receptores metabotrópicos de glutamato
AU2010203656A1 (en) 2009-01-07 2011-07-21 Scynexis, Inc. Cyclosporine derivative for use in the treatment of HCV and HIV infection
EP2403844A1 (en) * 2009-03-06 2012-01-11 F. Hoffmann-La Roche AG Heterocyclic antiviral compounds
EP2421831A1 (en) 2009-04-25 2012-02-29 F. Hoffmann-La Roche AG Heterocyclic antiviral compounds
ES2440001T3 (es) 2009-05-12 2014-01-27 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-A]piridina y su uso para el tratamiento o prevención de trastornos neurológicos y psiquiátricos
SG176018A1 (en) 2009-05-12 2011-12-29 Janssen Pharmaceuticals Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
BRPI1010900A2 (pt) * 2009-05-20 2016-03-15 Hoffmann La Roche compostos antivirais heterocíclicos
SG176976A1 (en) 2009-06-24 2012-02-28 Hoffmann La Roche Heterocyclic antiviral compound
HRP20161025T1 (hr) 2009-09-15 2016-11-04 Taigen Biotechnology Co., Ltd. Inhibitori proteaze hcv-a
BR112012005616A2 (pt) 2009-09-21 2016-06-21 Hoffmann La Roche compostos antivirais heterocíclicos
WO2011057989A1 (en) * 2009-11-11 2011-05-19 Basf Se Heterocyclic compounds having herbicidal action
AU2010317996A1 (en) 2009-11-14 2012-05-10 F. Hoffmann-La Roche Ag Biomarkers for predicting rapid response to HCV treatment
BR112012012085A2 (pt) 2009-11-21 2016-05-17 Hoffmann La Roche compostos antivirais heterocíclicos
CA2772285A1 (en) 2009-12-02 2011-06-09 F. Hoffmann-La Roche Ag Biomarkers for predicting sustained response to hcv treatment
ES2552455T3 (es) 2010-11-08 2015-11-30 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
CA2814998C (en) 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN103298809B (zh) 2010-11-08 2016-08-31 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
AU2012245387C1 (en) * 2011-04-22 2016-05-05 Signal Pharmaceuticals, Llc Substituted Diaminocarboxamide and Diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
RU2534613C2 (ru) 2013-03-22 2014-11-27 Александр Васильевич Иващенко Алкил 2-{ [(2r,3s,5r)-5-(4-амино-2-оксо-2н-пиримидин-1-ил)- -гидрокси-тетрагидро-фуран-2-илметокси]-фенокси-фосфориламино} -пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
IL279202B2 (en) 2014-01-21 2023-09-01 Janssen Pharmaceutica Nv Combinations containing positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic subtype 2 receptor and their use
US10537573B2 (en) 2014-01-21 2020-01-21 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
CN106810557B (zh) * 2015-11-27 2021-05-04 南京圣和药物研发有限公司 杂环化合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040034041A1 (en) * 2000-05-10 2004-02-19 Dashyant Dhanak Novel anti-infectives
AR036081A1 (es) * 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
AU2002365198A1 (en) * 2001-10-30 2003-07-30 Smithkline Beecham Corporation Novel anti-infectives

Also Published As

Publication number Publication date
CA2504385A1 (en) 2004-05-21
EP1560827A1 (en) 2005-08-10
CA2504385C (en) 2012-12-18
AU2003291670A1 (en) 2004-06-07
KR20050065670A (ko) 2005-06-29
WO2004041818A1 (en) 2004-05-21
MXPA05004670A (es) 2005-08-18
EP1560827B1 (en) 2010-12-29
EP2361913A1 (en) 2011-08-31
BR0315897A (pt) 2008-05-13
EP2361913A8 (en) 2012-04-18

Similar Documents

Publication Publication Date Title
PL376823A1 (pl) Środki przeciwzakaźne
EP1556053A4 (en) ANTI-INFLAMMATORY AGENTS
GB2392460B (en) Delayed-gelation solution
AU2003249738A8 (en) Ostoscope
AU2003297193A8 (en) Meta-web
AU2003252028A8 (en) Heterodiamondoids
IL173492A0 (en) Isothiazoloquinolones and related compounds as anti-infective agents
AU2003279495A8 (en) Alert-modeling
DE50303619D1 (en) Reibschweissvorrichtung
GB0207021D0 (en) Anti-bacterial agents
AU2003264900A8 (en) Cast-cutter
AU2003290818A8 (en) Topoisomerase-targeting agents
DE50304964D1 (en) Handhobelmaschine
AU2002367810A8 (en) Bis-transition-metal-chelate-probes
AU2003262681A8 (en) Hemo-aide
EP1709976A4 (en) EMT-INDUCING MEDIUM
DE10392833D2 (en) Geotextilie
AU2003253735A8 (en) Vacuolins
AU2002341221A8 (en) Honey-brandy
HK1082732A (en) Anti-infective agents
GB0204798D0 (en) Cycostatic agents
IL164811A0 (en) Vitamin-targeted inaging agents
AU2326P (en) Gavol Gazania rigens
AU2328P (en) Archley Arctotis fastuosa
AU2327P (en) Archnah Arctotis fastuosa

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)